W. Rachel Duan

No ORCID on file · 15 papers in corpus · active 2016-2018

Study types

  • article 13
  • rct 1

Condition tags

  • endometriosis 13
  • dysmenorrhea 4
  • chronic_pelvic_pain 2
  • dyspareunia 2
2018
Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
Obstetrics and gynecology ·doi:10.1097/aog.0000000000002933

ObjectiveTo evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyoma…

article 2018
Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment
Clinical pharmacology in drug development ·doi:10.1002/cpdd.640

The aim of these studies was to assess the safety and pharmacokinetics of elagolix, an oral nonpeptide gonadotropin-releasing hormone antagonist following oral administration in women with renal or hepatic impairment. Two phase 1 studies we…

article 2018
Long-term Effect of Elagolix on Bone Mineral Density in Women with Endometriosis-Associated Pain [38G]
·doi:10.1097/01.aog.0000533387.12236.72

INTRODUCTION: To evaluate the long-term effect of elagolix, an oral, non-peptide GnRH antagonist, on bone mineral density (BMD) in two 6-month (M) extension studies (Elaris EM-III and IV) of the pivotal, 6M, phase 3 studies (12M overall tre…

article 2018
Long-Term Outcomes of Elagolix in Women With Endometriosis
Obstetrics and gynecology ·doi:10.1097/aog.0000000000002675

OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain. METHODS: Elaris Endometriosis (EM)-III and -IV were exten…

article 2018
Long-Term Safety and Efficacy of Elagolix Treatment in Women With Endometriosis-Associated Pain [11OP]
·doi:10.1097/01.aog.0000533299.54528.7c

INTRODUCTION: Long-term safety and efficacy of elagolix, an oral, non-peptide GnRH antagonist for the management of endometriosis-associated pain, was evaluated in two 6-month (M) extension studies (Elaris EM-III and IV) of the pivotal, 6M,…

article 2017
Long-term effect of elagolix on bone mineral density: results from two phase 3 extension studies in women with endometriosis-associated pain
·doi:10.1016/j.fertnstert.2017.07.292
article 2017
Long-term effect of elagolix on the endometrium: results from two phase 3 extension studies in women with endometriosis-associated pain
·doi:10.1016/j.fertnstert.2017.07.147
article 2017
Long-Term Effect of Elagolix on the Endometrium: Results from Two Phase 3 Extension Studies in Women with Endometriosis-Associated Pain
·doi:10.1016/j.jmig.2017.08.051
article 2017
Long-term safety and efficacy of elagolix treatment in women with endometriosis-associated pain: primary results from two phase 3 extension studies
·doi:10.1016/j.fertnstert.2017.07.293
article 2017
Long-Term Safety and Efficacy of Elagolix Treatment in Women with Endometriosis-Associated Pain: Primary Results From Two Phase 3 Extension Studies
·doi:10.1016/j.jmig.2017.08.078
article 2017
Maintenance of endometriosis-associated pain reduction and quality of life improvement in phase 3 extension studies with elagolix
·doi:10.1016/j.fertnstert.2017.07.294
article 2017
O-GYN-MD-126 Primary Efficacy and Safety Results from Two Double-Blind, Randomized, Placebo-Controlled Studies Of Elagolix, an Oral Gonadotropin-Releasing Hormone Antagonist, in Women With Endometriosis-Associated Pain
·doi:10.1016/j.jogc.2017.03.067
rct 2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
The New England journal of medicine ·doi:10.1056/NEJMoa1700089

BACKGROUND: Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppres…

article 2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
·doi:10.1056/nejmoa1700089

Copyright © 2017 Massachusetts Medical Society. BACKGROUND Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, …

article 2016
Elagolix, an oral gonadotropin-releasing hormone antagonist, for the management of endometriosis-associated pain: safety and efficacy results from two double-blind, randomized, placebo-controlled studies
·doi:10.1016/j.fertnstert.2016.07.780